Evolocumab (Repatha) is a monoclonal antibody PCSK9 inhibitor that reduces LDL by up to 60% on top of statins. The FOURIER trial showed a 15% reduction in major cardiovascular events, with evidence of coronary plaque regression.
Research summaries are AI-generated from open-access peer-reviewed literature (PubMed Central, Cochrane, AHA/ACC). Content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.